STOCK TITAN

Findit Inc - FDIT STOCK NEWS

Welcome to our dedicated news page for Findit (Ticker: FDIT), a resource for investors and traders seeking the latest updates and insights on Findit.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Findit's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Findit's position in the market.

Rhea-AI Summary
BioRegenx, Inc. (FDIT) will showcase its innovative products at the Roth Conference, including Endocalyx Pro and GlycoCheck device, revolutionizing health and wellness. The AI Engine Technology from Docsun Biomedical Holdings, Inc. will also be discussed, offering transformative solutions for vital signs monitoring.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
BioRegenx, Inc. merged into Findit, Inc. and changed its name, with plans to up-list to OTC QB. The company's subsidiary, Microvascular Health Solutions, launched an updated GlycoCheck device, driving sales and monthly recurring revenue. Endocalyx Pro supplement saw impressive sales growth. The acquisition of DocSun Biomedical Holdings is set to boost revenue through a distribution agreement, with significant revenue potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
BioRegenx, Inc. successfully merged with Findit, Inc. (FDIT) and rebranded, aiming to up-list to OTC QB. Their subsidiary, Microvascular Health Solutions, launched an updated GlycoCheck device with strong sales. Endocalyx Pro supplement also shows impressive sales growth. The recent acquisition of DocSun Biomedical Holdings, Inc. positions BioRegenx for revenue generation through AI technology in the electric vehicle sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.86%
Tags
Rhea-AI Summary
BioRegenx, Inc. has announced a merger with Findit, Inc. and the successful acquisition of DocSun Biomedical Holdings, Inc., expanding its intellectual property and product portfolio. DocSun has signed a contract with a prominent international conglomerate to integrate its AI technology into various industries, including automotive and healthcare. Anticipated revenues from the licensing deal are expected to increase as the conglomerate releases new electric vehicles containing DocSun's technology into the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.92%
Tags
-
Rhea-AI Summary
FINDIT, Inc. (FDIT) has filed its 14C Information Statement, disclosing important details.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.46%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
56.52%
Tags
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.01%
Tags
none
Findit Inc

OTC:FDIT

FDIT Rankings

FDIT Stock Data

12.25M
31.05M
71.31%
Crude Petroleum and Natural Gas Extraction
Mining, Quarrying, and Oil and Gas Extraction
Link
US
Atlanta

About FDIT

.............................................................................................................................find it...........................................................................................................................................................................................................................................................................